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1. Summary statement of the proposal for inclusion 
 
The benzodiazepine midazolam has proven sedative, anxiolytic and amnesic properties. It is 
extensively used for premedication and procedural sedation in both adults and children. 
 
In comparison to other benzodiazepine and non-benzodiazepine drugs, midazolam is equally or more 
effective for premedication/preoperative sedation. No evidence exists that premedication with 
midazolam prolongs discharge time from hospital. Its efficacy and safety have been extensively 
studied in both adults and children. This contrasts its comparator drug, diazepam for which data in 
children and elderly are scarce or lacking.  
Midazolam is also effective for procedural sedation as a single drug or in combination with an opioid. 
As a single drug, adequate sedation for procedures in the emergency room, is achieved in over 90% 
of all procedures. Comparative efficacy was shown for propofol. Data are insufficient to determine 
comparative efficacy for procedural sedation for other drugs.  
 
When administered with the appropriate precautions, e.g. titration to effect, adequate monitoring and 
personnel to support ventilation, midazolam is very safe. No major adverse events were seen in 847 
adults who received midazolam for procedural sedation. Also, adverse effects can be antagonized with 
an effective antagonist, flumazenil. 
 
As midazolam is off-patent, drug costs are relatively low. Drug costs per procedure range from 
approximately 0.15 US$ to 2.6 US$ in an adult, depending on dose and country, with significantly 
lower costs in developing countries.  
 
2. Name of the focal point in WHO submitting or supporting the application 
 
3. Name of the organization(s) consulted and/or supporting the application 
 
Erasmus MC Sophia Children‟s Hospital, Rotterdam, the Netherlands 
 
4. International Nonproprietary Name (INN, generic name) of the medicine 
 
Midazolam 
 
5. Formulation proposed for inclusion; including adult and paediatric  
 
Intravenous formulation:  injection: 1 mg/mL 
Oral formulation: tablet, 7.5 mg, suspension 2 mg/mL 
 
6. International availability - sources, if possible manufacturers 
 
Please see addendum 1 
 
7. Whether listing is requested as an individual medicine or as an example of a 
therapeutic group  
 
Individual medicine 
 
8. Information supporting the public health relevance  
 
Invasive procedures are part of daily adult and pediatric practice. Many of these procedures are 
painful, stressful, and impossible to perform without immobilizing the patient. Therefore, procedural 
sedation is required to enable these procedures to be performed. Procedural sedation can be defined 
as the use of sedative, analgesic, or dissociative drugs in order to provide anxiolysis, analgesia, 
sedation, and motor control during painful or unpleasant procedures [1]. 
Indications for procedural sedation and analgesia can be divided into three categories: minor trauma 
(e.g. wound care, incisions and drainage, fractures and dislocations), instrumentation (e.g. lumbar 
puncture, renal biopsy, intravenous access, endoscopic procedures and cardiothoracic procedures) 
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and diagnostic imaging (ultrasonography, MRI and CT scan) [1]. These procedures are routinely 
performed outside the operating room, for example at the emergency department and at nursing 
wards. 
 
Effective procedural sedation guarantees predictable procedural success and timing (procedural point 
of view) and optimal procedural comfort and minimizing procedural stress and failure (patient‟s point of 
view). The primary goal of procedural sedation is patient comfort. The ideal sedation endpoint would 
be one at which the procedure can be successfully accomplished with as little distress to the patient as 
possible and with cardiopulmonary stability and retention of protective airway reflexes. Currently, 
intravenous midazolam is one of the drugs routinely used for procedural sedation.  
Registry data from the United States and Canada indicate that midazolam is used in 15-42% of all 
episodes of procedural sedation [2-4]. 
 
Besides procedural sedation, midazolam is also used as pre-operative medication to provide sedation 
and anxiolysis. Many patients are anxious before surgery. Since increased pre-operative anxiety is 
associated with poor postoperative behavioral and clinical recovery, up to 75% of anesthesiologists in 
the United States routinely administer sedative premedication to healthy adult patients who undergo 
surgery [5]. It is shown that patients treated with midazolam pre-operatively not only exhibit lower 
levels of anxiety, but they also report improved post-operative psychological and pain recovery [6].  
Thus, in addition to beneficial pre-operative effects, midazolam has also beneficial postoperative 
effects on patients undergoing surgery. 
 
9. Treatment details  
 
Dosage regimen 
 
Indication Adults <60 yrs of 
age  
Adults >60 yrs of age  
and debilitated or chronically ill 
patients 
Children 
“Conscious 
sedation”  
i.v.  
Starting dose: 2-
2,5 mg  
Titration dose: 1 
mg  
Total dose: 3,5-7,5 
mg  
i.v.  
Starting dose: 0,5-1 mg  
Titration dose: 0,5-1 mg  
Total dose: < 3,5 mg  
i.v. 6 months - 5 years: 
Starting dose: 0,05-0,1 
mg/kg  
Total dose: < 6 mg  
i.v. 6-12 years: 
Startdose: 0,025-0,05 
mg/kg  
Total dosis: < 10 mg  
rectal > 6 months  
0,3-0,5 mg/kg  
  
Amnesia induction   
Anxiety  
Preoperative 
sedation 
i.v. 
1-2 mg titrated  
i.m. 
0,07-0,1 mg/kg  
 
i.v.  
Startdose: 0,5 mg  
Slowly titrate towards effect 
i.m.  
0,025-0,05 mg/kg  
rectal > 6 months  
0,3-0,5 mg/kg  
i.m. 1-15 years 
0,08-0,2 mg/kg  
Oral > 6 months 
0.25-1 mg/kg 
 
Clinical guidelines 
 
1. WHO Pediatric Formulary:  
 
Midazolam is included in the WHO pediatric formulary for palliative procedures, but not for the 
indications of this application (premedication, procedural sedation). 
 
Formulary text:  
ATC code: N05CD08 
Injection: 1 mg/ml; 5 mg/ml 
Indications: Palliative situations such as seizures, anxiety and agitation. 
Contraindications: Consider the relevance of these listed contraindications in palliative care. Acute or 
severe pulmonary insufficiency; sleep apnoea syndrome; severe liver disease; myasthenia gravis. 
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Dose: For all indications in a palliative care setting. 
SC or IV injection: Child all ages 0.05–0.15 mg/kg every 1–2 hours. 
Continuous SC or IV infusion: Child all ages 10 micrograms/kg/hour by continuous SC or IV infusion, 
initially, and titrate to effect. There is considerable variability in the dose required. 
Oral: Child all ages 0.3–0.5 mg/kg (maximum 15 mg) as a single dose. Use the parenteral form; bitter 
taste can be disguised in apple juice or chocolate sauce. 
Buccal or intranasal: Child all ages 0.2–0.5 mg/kg per dose (maximum 10 mg) as required. Use the 
parenteral form. 
 
2. Other guidelines 
- Clinical policy from American College of Emergency Physicians: procedural sedation and analgesia 
in the emergency department:  
Drug Administration Recommendations: The combination of fentanyl and midazolam is effective for 
procedural sedation and analgesia in the ED [7]. 
 
- AGA Institute Review of Endoscopic Sedation 2007 [8]. 
Recommendation: The majority of patients can be sedated adequately by using a combination of an 
opioid and a benzodiazepine. 
 
Need for monitoring 
Midazolam hydrochloride must never be used without individualization of dosage particularly when 
used with other medications capable of producing central nervous system depression. Prior to the 
intravenous administration of midazolam hydrochloride in any dose, the immediate availability of 
oxygen, resuscitative drugs, age- and size-appropriate equipment for bag/valve/mask ventilation and 
intubation, and skilled personnel for the maintenance of a patent airway and support of ventilation 
should be ensured. Patients should be continuously monitored with some means of detection for early 
signs of hypoventilation, airway obstruction, or apnea, i.e., pulse oximetry. Hypoventilation, airway 
obstruction, and apnea can lead to hypoxia and/or cardiac arrest unless effective countermeasures 
are taken immediately [9]. 
 
10. Summary of comparative effectiveness in a variety of clinical settings 
 
Indication: premedication 
 
 Identification of clinical evidence 
 
Pubmed was searched from inception to July 2010. The following search strategy was used: 
Midazolam AND ((premedication OR pre-operative sedation) OR (preoperative sedation) OR (pre-
operative medication) OR (preoperative medication) OR pre-operative). All case reports (unless 
specifically addressing adverse events), non systematic reviews, cohort studies, papers not reporting 
on midazolam were excluded. Two systematic reviews were identified. Cox et al. evaluated the 
efficacy of midazolam used as premedication and Dahmani et al. who reviewed efficacy of midazolam 
and clonidine as premedication in the pediatric population [10]. We also searched Micromedex Drug 
Evaluations and clinical guidelines for relevant papers. In addition, the Cochrane Database was 
searched using: midazolam OR premedication. One relevant Cochrane review was found for adults on 
the difference of time to discharge from hospital in patients who received anxiolytic medication for day 
surgery [11]. For children, no relevant Cochrane reviews were identified. 
 
 Summary of available data  
 
Adults 
 
A Cochrane review found no evidence of a difference in time to discharge from hospital, assessed by 
clinical criteria, in patients who received anxiolytic premedication versus placebo for day case surgery 
[11]. Of the 17 studies identified in this review, overall quality was poor. Of these studies, seven 
involved midazolam, as single agent, in different dosages and administration routes [12-18]. 
Significantly deeper sedation, both preoperativaly and postoperatively was found for midazolam vs. 
placebo. Four of these studies specifically looked at discharge time, but did not show a difference in 
discharge time between midazolam and placebo [12-13, 15, 17].  
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In addition to these 7 studies on midazolam for premedication in adult day case surgery, another 18 
studies comparing midazolam vs. placebo for premedication for a variety of surgical procedures were 
found [6, 19-35]. 
Midazolam doses ranged from 0.05 and 0.2 mg/kg IV, PO, IM or SL. For most studies, quality of study 
reporting of these studies was moderate to low, with often missing information on randomization 
and/or blinding procedures. All studies (n=16) with sedation and/or anxiety as outcome measure, 
showed significant preoperative sedation and/or anxiety reduction in patients receiving midazolam as 
premedication. In addition, midazolam was associated with amnesia and prolonged impairment when 
compared to placebo. In one of these studies, in elderly patients, prolonged discharge time was 
observed after midazolam premedication [20]. This difference with the other studies discussed above 
may be explained by prolonged plasma elimination and increased sensitivity to midazolam in the 
elderly population.  
 
One study showed that midazolam as premedication (3.5 mg PO) blunts the hormonal stress response 
to surgical procedures [30]. Another study showed a significant reduction in preoperative oxygen 
consumption and energy expenditure, when midazolam (70 mcg/kg IV) was administered as 
premedication [29].  
 
Most studies only looked at sedation, anxiety levels and amnesia as efficacy outcome measures. An 
additional, but maybe more important outcome for adequate sedation and anxiolysis, is the possible 
positive effect on postoperative clinical recovery. A well designed, but small study in 56 adult patients, 
showed a reduction in postoperative pain and anxiety, but could not identify a difference in most 
postoperative clinical outcomes, such as time to discharge from PACU, vomiting and nausea, overall 
health outcome and quality of life [6]. Interestingly, up to 7 days postoperatively, self-reported pain and 
analgesic consumption, were significantly decreased with midazolam versus placebo, respectively (0% 
versus 17%, p=0.03). Anxiety levels were also lower for midazolam up to 30 days postoperatively. The 
only significant between-group difference in clinical recovery was a reduction in self-reported infection 
at 1 week for midazolam versus placebo recipients (0% versus 16%, p=0.04). 
 
In summary, the available evidence shows, that midazolam is effective in reducing anxiety and 
increasing sedation when given as premedication in adult patients undergoing invasive procedures. 
Although, psychomoter impairment may be present up to 4 hrs postoperatively, evidence appears to 
be lacking that midazolam premedication actually increases discharge time.  
 
Children 
 
A systematic review in 2006 by Cox at al. evaluated efficacy of midazolam as a premedication, 
focusing on behavioral outcomes. A total of 30 out of 171 randomized controlled trials (midazolam vs 
placebo or comparator) were identified. The authors concluded that; „Premedication with midazolam 
0.5 mg/kg administered 20–30 min preoperatively, is effective in reducing both separation and 
induction anxiety in children (grade A recommendation), with minimal effect on recovery times. 
However improved postoperative behavioural outcomes in the post-anesthesia care unit, or at home 
cannot be predicted on a consistent basis” [36]. 
Using the above mentioned search strategy, we identified 19 double blinded randomized controlled 
trials comparing efficacy of midazolam versus placebo. In most trials, primary outcome measurements 
were level of sedation and anxiety. In 18 out of 19 RCT‟s midazolam was shown to significantly 
decrease anxiety or increase the level of sedation prior to general anesthesia, as compared to placebo 
[37-55]. Midazolam dosage ranged from 0.25-0.75 mg/kg given either orally, rectally or 
buccal/sublingual. Only Bevan et al. did not find a difference in depth of sedation or anxiety of 
midazolam compared to placebo using an oral dose of 0.5 mg/kg [56]. 
Two studies addressed occurrence or reduction of postoperative vomiting and nausea after general 
anesthesia, comparing midazolam to placebo. Both Riad et al. and Splinter et al. showed a reduction 
in episodes of nausea or vomiting in children after strabismus correction or tonsillectomy using low 
dose intravenous midazolam (0.05-0.075 mg/kg) [57-58]. 
Several studies showed prolonged recovery after general anesthesia in children premedicated with 
midazolam although this did not lead to prolonged hospital stay [47, 49, 56, 59-60]. 
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In summary, the available evidence shows, that midazolam is effective in reducing anxiety and 
increasing sedation when given as premedication in pediatric patients undergoing general anesthesia. 
Although, there seems to be an effect on delayed recovery, it does not prolong hospital stay.  
 
 Summary of available estimates of comparative effectiveness 
 
Adults 
 
In adults, midazolam for premedication has been compared with many other drugs for premedication, 
such as benzodiazepines (temazepam [18, 61-63], diazepam [15, 27, 33-34, 64], triazolam [15] 
alprazolam [12]), alpha 2-adrenoceptor agonists (clonidine [23-24, 29], dexmedetomidine [32, 65-66], 
first generation antihistamines (droperidol [31, 67-68], phenothiazine [31], hydroxyxizine [35]), 
ketobemidone [69], butorphanol [70], zolpidem [28] and melatonin [19, 21-22].   
Diazepam and midazolam are similar in efficacy for producing sedation prior to short surgical 
procedures. However, midazolam produces a greater degree of amnesia and, when given 
intramuscular, less pain on injection, and less phlebitis than diazepam [71]. Midazolam in doses 
between 5 and 15 mg IV/IM/PO was equally or more effective to induce sedation and anxiolysis when 
compared to these other drugs. Also, the amnesic properties of midazolam appear more evident than 
for other drugs.  
 
Children 
 
Several studies compare the efficacy of midazolam for premedication with other sedatives or 
analgesics. Midazolam is compared with melatonin [38, 41], fentanyl [72], clonidine [10, 44, 73-77] 
ketamine [78-87] , diazepam/meripidine [88], chloralhydrate [89-90] and dexmedetomidine [91]. 
 
A recent systematic review evaluated comparative efficacy of benzodiazepines and clonidine, 
including five trials that compared midazolam with clonidine. The authors conclude; “Premedication 
with clonidine, in comparison with midazolam, exhibited a superior effect on sedation at induction, 
decreased the incidence of emergence agitation and produced a more effective early post-operative 
analgesia” [10]. Critical evaluation of this review reveals that in two trials sedation with midazolam is 
significantly more effective in the pre operative setting compared to clonidine [44, 73], or, at least as 
effective as clonidine [74-75]. One study showed more effective sedation with clonidine compared to 
midazolam. However there was no significant difference in anxiety reduction or acceptance of mask 
ventilation between both groups. Moreover midazolam achieved its effect significantly faster compared 
to clonidine [76]. Only one RCT showed clonidine is superior to midazolam with regards to reduced 
anxiety, increased sedation and mask acceptance [77]. 
 
Several RCT‟s addressed relative efficacy of midazolam and ketamine. Most studies find either no 
significant difference in efficacy [78-86] or favor midazolam in reduction of anxiety and increased 
sedation[87]. 
 
Several authors showed increased levels of sedation with midazolam premedication compared to 
rectal chloralhydrate [89-90]. Compared to diazepam in combination with meperidine, midazolam is as 
effective [92] or more effective [88]. Intranasal dexmedetomidine produces more sedation than oral 
midazolam, but with similar and acceptable cooperation [91]. 
Midazolam was found to be the drug of preference in comparison to fentanyl for the majority of 
patients [72]. Two RCT placebo controlled addressed melatonin and midazolam. Both studies showed 
midazolam is as effective or more effective [38, 41]. 
 
Indication: Procedural sedation 
 
 Identification of clinical evidence  
 
Pubmed was searched using the following search strategy: Midazolam AND ((procedural sedation) 
OR (short-term procedures) OR (short term procedures)). For pediatric studies the following search 
terms were added: child*[tw] OR infan*[tw] OR pediatr*[tw] OR paediatr*[tw] All case reports (unless 
specifically addressing adverse events), non systematic reviews, cohort studies and papers not 
reporting on midazolam use were excluded.  
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A 2008 systematic review was found in this search comparing safety and clinical effectiveness of 
midazolam versus propofol for procedural sedation in the emergency department [93]. 
Another 2008 systematic review was identified of clinical trials for sedation in gastrointestinal 
endoscopy [94].  
One systematic review was identified comparing efficacy and safety of midazolam versus ketamine for 
procedural sedation in children in the emergency department[95]. In addition two reviews were 
identified evaluating drug efficacy in procedural sedation and analgesia in children [96-97]. 
Micromedex Drug Evaluations
®
 and clinical guidelines were searched for relevant papers. In addition 
the Cochrane Library was searched using the following search terms: midazolam OR sedation. This 
search yielded 65 results. The following review was relevant for adults: Conscious sedation and 
analgesia for oocyte retrieval during in vitro fertilisation procedures [98]. For pediatric procedural 
sedation another two reviews were relevant: „Sedation versus general anaesthesia for provision of 
dental treatment in under 18 year olds‟ [99] and „Sedation of anxious children undergoing dental 
treatment‟ [100]. 
 
 Summary of available data 
 
Adults 
 
In 2008, Hohl at al performed a systematic review comparing midazolam with propofol for procedural 
sedation in the Emergency Room setting [93]. The secondary endpoint was the mean difference in the 
proportion of patients who were successfully sedated and for whom the indicating medical procedure 
could be performed. 
Overall procedural success rate for patients sedated with midazolam was 89.9 (83.2, 94.6) %. When 
trials with a Jadad score <3 (poor study quality) were removed from the analysis, procedural success 
rate was even higher (93.5 (87.0, 97.8%)). 
 
The American College of Emergency Physicians published the guideline: procedural sedation and 
analgesia in the emergency department. For this guideline, a systematic review was performed for all 
aspects of procedural sedation. A level B recommendation was made that the combination of fentanyl 
and midazolam is effective for procedural sedation and analgesia in the ED [7].  
 
Another setting for frequent procedural sedation is gastrointestinal endoscopies. Most studies in this 
setting compared midazolam with placebo or another benzodiazepine. In 2007, the AGA Institute 
published a Review of Endoscopic Sedation [8]. Whenever possible, the statements and 
recommendations were developed systematically from an evidence-based analysis of the literature. 
The guidelines state that the majority of patients can be sedated adequately by using a combination of 
an opioid and a benzodiazepine, however, without mentioning the strength of evidence.  
A 2008 systematic review and meta-analysis of randomized, controlled trials of moderate sedation for 
routine endoscopic procedures identified 16 trials comparing midazolam to placebo. Only 2 trials were 
of good quality (Jadad score ≥ 4) [94]. 91% of patients were satisfied with their level of sedation, vs. 
85% of physicians.  
 
Children 
 
Two Cochrane systematic reviews were identified addressing continuous sedation in the pediatric 
patient during dental procedures. Both reviews concluded that there were insufficient good quality 
studies to make any recommendations concerning the choice of medication [99-100]. 
We could identify only eight placebo controlled randomized trials evaluating midazolam for procedural 
sedation in children [101-107]. These studies all show that midazolam is more effective than placebo 
for sedation for minor procedures. 
 
 Summary of available estimates of comparative effectiveness 
 
Adults 
The efficacy of procedural sedation in the emergency room was compared for midazolam versus 
propofol in systematic review. Although there appeared to be a small advantage of propofol over 
midazolam in the point estimates of the proportion of successful PS in two RCTs, the pooled 
difference between the agents remained statistically insignificant in all sensitivity analyses [93]. 
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The Cochrane review on conscious sedation and analgesia for oocyte retrieval during in vitro 
fertilisation procedures concluded that there is insufficient evidence to determine the effect of different 
methods of pain relief when compared with conscious sedation and analgesia used during oocyte 
recovery [98]. Hence, not one drug can be identified as superior for this indication. 
 
The ACEP guideline for procedural sedation also provided a level B recommendation that 
propofol can be safely administered for procedural sedation and analgesia in the ED, which is a 
recommendation with similar strength of evidence as the combination benzodiazepine/opioid. 
Although diazepam is approved for sedation in adult patients by the FDA. strength of evidence 
(Category B) is less than for midazolam (Category A). While a Level C recommendation was made for 
etomidate in the same setting [7].  
 
More than 98% of endoscopists in the United States routinely administer sedation during upper and 
lower endoscopies. Endoscopists prefer the use of midazolam instead of diazepam because of its 
favorable pharmacologic profile [108]. A systematic review comparing sedative regimens showed high 
level of physician and patient satisfaction and a low risk of serious adverse events with all currently 
available agents [94]. In addition, meta analysis of 8 studies showed that midazolam provided superior 
patient satisfaction to diazepam (RR Z 1.18, range 1.07-1.29) and less frequent memory of upper 
gastrointestinal endoscopy (RR Z 0.57, range 0.50-0.60) versus diazepam. No difference in patient 
satisfaction was found when midazolam was compared with propofol. There does not appear to be an 
advantage of sedation with a combination of midazolam and opiates compared with midazolam alone 
for upper gastrointestinal endoscopy. 
 
Children 
 
A systematic review conducted in 2007 evaluated the literature for comparison of efficacy and safety 
of midazolam and ketamine for procedural sedation in the emergency department. Four papers were 
included in the analysis. Based on these studies midazolam and ketamine have the same safety 
profile in the emergency department. Although midazolam reduces post operative vomiting there 
seems to be a preference for ketamine in parent surveys [95]. As noted in this review there are no 
single drug studies comparing midazolam and ketamine. Most studies evaluate treatment regimes 
including and comparing multiple drugs. 
 
Liddo et al. compared efficacy and safety of etomidate and midazolam, showing shorter induction and 
recovery times for etomidate with higher efficacy compared to midazolam [109]. However etomidate is 
assocated with adrenal insufficiency and should therefore be used with care in children [110] and is 
not recommended in children below the age of 10 years [111].  
 
There remains a paucity of high quality randomized controlled trials addressing efficacy and safety of 
single drugs. Since the indications of procedural anesthesia vary, several combinations of midazolam 
and morphine or morphine derivates have been published.  
Two systematic reviews conclude that midazolam in combination with fentanyl or ketamine provides 
effective sedation and analgesia during painful procedures in children [96-97].  
The systematic review from 2004 by Migita et al, evaluated efficacy and safety of several sedatives 
and analgesics frequently used in the emergency department. The authors concluded that midazolam 
in combination with fentanyl is effective in providing procedural sedation and analgesia in 91-100% of 
all patients (recommendation level B). However, this combination is associated with a higher rate of 
respiratory depression. Therefore adequate monitoring and facilities to secure respiration are essential 
(recommendations level B) [97]. The systematic review in 2006 by Russell et al concluded that 
midazolam in combination with ketamine provides adequate sedation and analgesia in fracture 
reduction in children and seems superior to fentanyl-midazolam and propofol-fentanyl [96]. 
 
Padmanabhan et al evaluated midazolam-ketamine versus propofol-ketamine, midazolam-tramadol 
and propofol-tramadol in pediatric dental patients. The combination of midazolam-ketamine was the 
most effective combination realizing adequate sedation levels in 81% of patients [112]. Two other 
RCT‟s evaluating midazolam-ketamine versus ketamine [113] or midazolam-fentanyl [114] published 
after 2006 show ambiguous results. However both studies show there is additional value of midazolam 
in procedural sedation. 
A combination of midazolam with dexmedetomidine, pentobarbital/fentanyl or ketamine and propofol 
seemed safe and effective in children undergoing MRI [115-118]. 
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Summary of comparative evidence on safety 
 
 Estimate of total patient exposure to date 
 
Midazolam has been used extensively since the mid 80‟s for short- and long-term sedation in adult 
and pediatric patients. Registry data from the United States and Canada indicate that midazolam is 
used in 15-42% of all episodes of procedural sedation [2-4]. 
 
 Description of adverse effects/reactions 
 
Fluctuations in vital signs were the most frequently seen findings following parenteral administration of 
midazolam in adults and included decreased tidal volume and/or respiratory rate decrease (23.3% of 
patients following IV and 10.8% of patients following IM administration) and apnea (15.4% of patients 
following IV administration), as well as variations in blood pressure and pulse rate. The majority of 
serious adverse effects, particularly those associated with oxygenation and ventilation, have been 
reported when midazolam hydrochloride is administered with other medications capable of depressing 
the central nervous system. The incidence of such events is higher in patients undergoing procedures 
involving the airway without the protective effect of an endotracheal tube (e.g., upper endoscopy and 
dental procedures) [9]. 
 
In a systematic review of the literature Hohl et al. analyzed 28 articles studying more than 3,000 
patients exposed to either propofol or midazolam. The total number of patients exposed to midazolam 
in the studies was 847. The occurrence of minor AEs was too heterogeneous to analyze, owing to 
varying definitions and reporting among individual studies. A major AE was defined as when one of 
the following was reported: death, disability, hospital admission, prolonged ED stay, intubation and/or 
vomiting with aspiration pneumonitis. The overall probabilities of major AEs were 0 in 847 (0%; 95% CI 
= 0% to 0.45%) for patients treated with midazolam [93].  
 
About 3.4% of children scheduled for elective surgery have been reported to develop paradoxical 
reactions following premedication with intravenous midazolam. These reactions may occur at variable 
times after administration and include restlessness, violent behavior, physical assault, acts of self-
injury and need for restraints [119]. 
 
  Identification of variation in safety due to health systems and patient factors 
 
Geriatric patients 
 
Because geriatric patients may have altered drug distribution and diminished hepatic and/or renal 
function, reduced doses of midazolam are recommended. Intravenous and intramuscular doses of 
midazolam should be decreased for elderly and for debilitated patients and subjects over 70 years of 
age may be particularly sensitive. These patients will also probably take longer to recover completely 
after midazolam administration for the induction of anesthesia. Administration of IM and IV midazolam 
to elderly and/or high risk surgical patients has been associated with rare reports of death under 
circumstances compatible with cardio-respiratory depression. In most of these cases, the patients also 
received other central nervous system depressants capable of depressing respiration, especially 
narcotics. Source FDA drug label [9]. 
 
Pediatric patients 
 
As a group, pediatric patients generally require higher dosages of midazolam (mg/kg) than do adults. 
Younger (between 3 months and six years) pediatric patients may require higher dosages (mg/kg) 
than older pediatric patients, and may require closer monitoring. In obese pediatric patients, the dose 
should be calculated based on ideal body weight. When midazolam is given in conjunction with 
opioids or other sedatives, the potential for respiratory depression, airway obstruction, or 
hypoventilation is increased. The health care practitioner who uses this medication in pediatric patients 
should be aware of and follow accepted professional guidelines for pediatric sedation appropriate to 
their situation.  
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Midazolam hydrochloride should not be administered by rapid injection in the neonatal population. 
Severe hypotension and seizures have been reported following rapid IV administration, particularly, 
with concomitant use of fentanyl. Source FDA drug label [9].  
A large prospective descriptive study by Pitetti et al. evaluated 14386 pediatric patients undergoing 
procedural sedation. In this cohort midazolam alone did not result in any adverse effects, whereas 
midazolam-fentanyl was associated with a higher rate of complications: 9,7% [120]. A prospective 
study including almost 800 children after procedural sedation evaluated post operative complications. 
Midazolam/fentanyl combinations were associated with a higher rate of post operative vomiting and 
nausea, whereas the combination of midazolam and ketamine had the least post operative 
complications [121]. 
 
 Summary of comparative safety against comparators 
 
The overall probability of major AEs was 1 in 2,453 for patients treated with propofol (0.04%; 
95% CI = 0.01% to 0.23%). No significant difference between midazolam and propofol in the 
proportion of major AEs was found (p = 0.56). Because of the resulting clinical heterogeneity of the 
studies in the systematic review, minor AEs could not be pooled into a meaningful summary statistic. 
Hence, resulting in no clinical or statistical difference in the risk profile between these agents [93]. 
 
Propofol, possessing different risks and benefits from traditional sedative agents such as 
benzodiazepines and opioids, has rapidly gained popularity. The FDA product label for propofol 
contains a warning that “propofol should be administered only by persons trained in the administration 
of general anesthesia.” In addition, there have been reports in which failure to use aseptic technique 
when handling propofol injection emulsion was associated with microbial contamination of the product 
and with fever, infection, sepsis, other life-threatening illness, and death. Especially in poor resource 
settings, where hygienic circumstances may not be optimal, the use of propofol may be associated 
with increased risk of microbial contamination [122]. 
 
The adverse event profile of midazolam and diazepam is largely the same, inherent to their 
mechanism of action and is largely dose-dependent [123]. A safety advantage of benzodiazepines 
over propofol, alpha 2-adrenoceptor agonists or antihistamines is the availability of an antidote, 
flumazenil. Flumazenil has been shown to easily and safely antagonize the benzodiazepine effect and 
related adverse events (such as respiratory depression) [123]. 
 
11. Summary of available data on comparative cost and cost-effectiveness within the 
pharmacological class or therapeutic group 
 
 Summary of comparative costs against comparators 
 
Reported prices for the IV injection solution (1 mg/ml) price ranges between 0.05 and 1.1 US$ per unit 
(1 ml) [124] [125] The unit price (1 ml) is 0.05 US$ in Peru, 0.11 US$ in Honduras, South Africa, the 
Netherlands and 0.16 US$ in Canada (18211306). Prices for the 5 mg/ml IV injection solution range 
from 0.15 to 0.94 US$ per unit (1ml).  
With an average midazolam dose for sedation ranging from 0.07-0.2 mg/kg, this amounts to a 
variation in price per procedure between 0.15 US$ and 2.6 US$ for a 70 kg adult, depending on 
country and solution used.  
Oral midazolam (15mg tablet) price is 0.26 US$ in the Netherlands [125]. 
 
Diazepam, which is indicated for premedication and sedation for endoscopic procedures, but not for 
other procedural sedation, is given in doses ranging from 5-15 mg po, IM or IV. The comparable 
midazolam dose for oral administration is 5-10 mg. Midazolam vs diazepam prices compare as 0.26 
US$ vs. 0.014-0.05 US$. 
The comparable midazolam dose for IV administration in 5-10 mg. Midazolam vs diazepam prices for 
IV administration compare as 0.15 US$ and 2 US$ vs. 0.1-0.5 US$. 
 
International propofol prices (2009) range between 0.08 US$ and 0.15 US$ per mL (10mg/mL) for the 
following countries: South Africa, Honduras, Senegal, Eastern Caribbean States, Costa Rica [124]. 
The average cost for 20mg/ml ampoule in Canada amounts to 2.9 US$, 2007 price level [126]. For the 
average procedure 1-3 mg/kg is given, which amounts to 7 to 21 mL for a 70kg adult. As leftover drug 
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is advised to be discarded, one or two 10 ml ampoules will be used which amounts to 0.80 US$ to 
2.90 US$ per procedure. 
 
 comparative cost-effectiveness presented as range of cost per routine outcome  
 
Adult 
 
Hohl et al [126] performed a cost-effectiveness analysis comparing midazolam with propofol for 
procedural sedation in the emergency room in a community or urban hospital in North America. All 
costs associated with procedural sedation in this setting were taken into account, including cost of ER 
visit, labor costs, medication costs and adverse event costs. In addition, mean difference in recovery 
times, the probabilities of successful procedural sedation (PS) and major AEs, and the drug doses 
associated with each sedation strategy were incorporated in the analysis. Based on this analysis, the 
authors showed that due to improved recovery times, PS with propofol was cost-saving in comparison 
to midazolam. The researches were unable to compare the use of midazolam against other agents 
such as ketamine, ketafol, etomidate, or methohexital, because insufficient comparative data were 
available. 
 
Pediatric 
A similar cost effectiveness study was performed by Pershad et al. in the pediatric emergency 
department [117].Total costs were calculated by assessing ED resource utilization associated with 
uncomplicated PSA (procedural sedation and anesthesia) and with PSA complicated by adverse 
events in a North American emergency department. When patients experienced emesis, recovery 
agitation, respiratory depression, lidocaine toxicity, or regional block failure, it was assumed that 
patients would require 1 additional hour of ED stay. 
Under baseline assumptions, the propofol/fentanyl regimen was the most cost-effective choice 
(expected cost, 84.06 US dollars), followed by axillary block (88.18 US dollars), ketamine/midazolam 
(105.32 US dollars), and fentanyl/midazolam (159.79 US dollars), respectively. Among PSA regimens 
during forearm fracture manipulation in the pediatric ED, propofol/fentanyl was the most cost-effective 
regimen followed by axillary block, ketamine/fentanyl and fentanyl/midazolam. 
 
Maruf et al. compared ketamine-diazepam (A) to midazolam-fentanyl (B). Sedation regimen of group B 
was five times more costly than group A. Both the regimens were found safe and effective for pediatric 
sedation during MRI, but ketamine, diazepam combination found more cost effective[118].  
Both studies evaluated a combination of drugs making cost evaluations for midazolam alone 
impossible. 
 
Summary of regulatory status of the medicine  
 
The following midazolam formulations are registered in the Netherlands for procedural sedation and 
premedication in both adults and children [127]: 
RVG 21297 Midazolam 1 mg/ml, solution for injection 
RVG 21299 Midazolam 5 mg/ml, solution for injection 
RVG 10539 Dormicum 15 mg, tablets 
RVG 13027 Dormicum 7,5 mg, tablets 
 
Midazolam is also registered in the US (solution for injection, tablets, oral syrup) for procedural 
sedation and premedication in both adults and children (Level A evidence) [9].  
 
12. Availability of pharmacopoeial standards  
 
European Pharmacopoeia [128]: standard available 
United States Pharmacopeia [129]: standard available 
British Pharmacopeia [130]: standard available 
WHO International Pharmacopeia [131]: no standard available 
 
13. Proposed (new/adapted) text for the WHO Model Formulary 
 
Advice: follow FDA product label [9]  
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Addendum 1 
 
Tradenames and manufacturers. Source:Micromedex®, accessed Nov 2010. 
 
Tradename List for midazolam: 
Name, Form & Strength Contact 
Anesfar Fahrenheit, Indon. 
Apo-Midazolam - 1 MG/ML - Injectable Apotex 
Apo-Midazolam - 5 MG/ML - Injectable Apotex 
Benzosed Troika, Venez. 
Damizol Specifar, Gr. 
Demizolam Dem, Turk. 
Doricum (DI) Roche, Venez. 
Dormicum (FM) Roche, Israel 
Dormicum EGIS, Hung. 
Dormicum Roche, Austria 
Dormicum Roche, Belg. 
Dormicum Roche, Cz. 
Dormicum Roche, Denm. 
Dormicum Roche, Fin. 
Dormicum Roche, Ger. 
Dormicum Roche, Gr. 
Dormicum Roche, Hong Kong 
Dormicum Roche, Indon. 
Dormicum Roche, Malaysia 
Dormicum Roche, Mex. 
Dormicum Roche, Neth. 
Dormicum Roche, Norw. 
Dormicum Roche, Philipp. 
Dormicum Roche, Pol. 
Dormicum Roche, Port. 
Dormicum Roche, S.Afr. 
Dormicum Roche, Singapore 
Dormicum Roche, Spain 
Dormicum Roche, Swed. 
Dormicum Roche, Switz. 
Dormicum Roche, Thai. 
Dormicum Roche, Turk. 
Dormire Cristalia, Braz. 
Dormium Uniao Quimica, Braz. 
Dormixal Demo, Gr. 
Dormizol (DI) Duopharma, Philipp. 
Dormonid Roche, Braz. 
Dormonid Roche, Chile 
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Fortanest Kalbe, Indon. 
Fulsed (FM) Ranbaxy, Cz. 
Fulsed Ranbaxy, Malaysia 
Fulsed Ranbaxy, Singapore 
Fulsed Ranbaxy, Ukr. 
Hipnazolam (FM) Sigma, Braz. 
Hipnoz Pharos, Indon. 
Hypnovel - 5 MG/ML - Injectable Roche 
Hypnovel Roche, Austral. 
Hypnovel Roche, Fr. 
Hypnovel Roche, Irl. 
Hypnovel Roche, NZ 
Hypnovel Roche, UK 
Ipnovel Roche, Ital. 
Midacum Hexal, S.Afr. 
Midanium Cipla-Medpro, S.Afr. 
Midanium Polfa Warszawa, Pol. 
Midaselect (FM) Curasan, Ger. 
Midazepin Behrens, Venez. 
Midazolam - 1 MG/ML - Injectable Faulding Laboratories 
Midazolam - 1 MG/ML - Injection Liquid Novopharm 
Midazolam - 1 MG/ML - Injection Solution Hospira 
Midazolam - 5 MG/ML - Injectable Faulding Laboratories 
Midazolam - 5 MG/ML - Injection Liquid Novopharm 
Midazolam - 5 MG/ML - Injection Solution Hospira 
Midazolam Hydrochloride - 1 MG/ML - 
Injectable 
Apotex 
Midazolam Hydrochloride - 1 MG/ML - 
Injection Solution 
Abbott Laboratories 
Midazolam Hydrochloride - 1 MG/ML - 
Injection Solution 
APP Pharmaceuticals 
Midazolam Hydrochloride - 1 MG/ML - 
Injection Solution 
Baxter Healthcare 
Midazolam Hydrochloride - 1 MG/ML - 
Injection Solution 
Cura Pharmaceuticals 
Midazolam Hydrochloride - 1 MG/ML - 
Injection Solution 
Hospira 
Midazolam Hydrochloride - 1 MG/ML - 
Injection Solution 
Hospira 
Midazolam Hydrochloride - 1 MG/ML - 
Injection Solution 
Wockhardt USA 
Midazolam Hydrochloride - 2 MG/ML - 
Oral Syrup 
Precision Dose 
Midazolam Hydrochloride - 2 MG/ML - 
Oral Syrup 
Ranbaxy Pharmaceuticals 
Midazolam Hydrochloride - 2 MG/ML - Roxane Laboratories 
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Oral Syrup 
Midazolam Hydrochloride - 5 MG/ML - 
Injectable 
Apotex 
Midazolam Hydrochloride - 5 MG/ML - 
Injection Solution 
Abbott Laboratories 
Midazolam Hydrochloride - 5 MG/ML - 
Injection Solution 
Baxter Healthcare 
Midazolam Hydrochloride - 5 MG/ML - 
Injection Solution 
Cura Pharmaceuticals 
Midazolam Hydrochloride - 5 MG/ML - 
Injection Solution 
Hospira 
Midazolam Hydrochloride - 5 MG/ML - 
Injection Solution 
Hospira 
Midazolam Hydrochloride - 5 MG/ML - 
Injection Solution 
Wockhardt USA 
Midazolam Hydrochloride - Preservative-
Free - 1 MG/ML - Injection Solution 
Cura Pharmaceuticals 
Midazolam Hydrochloride - Preservative-
Free - 5 MG/ML - Injection Solution 
Cura Pharmaceuticals 
Midazolam Hydrochloride-Sodium 
Chloride - 1 MG/ML - Injection Solution 
Pharmedium Services 
Midazolam Injection Bp - 1 MG/ML - 
Injectable 
Baxter 
Midazolam Injection Bp - 5 MG/ML - 
Injectable 
Baxter 
Midazolam Injection BP 2010    
Midazolam Injection USP 32    
Midazolam Oral Solution BP 2010    
Midazol (DI) Taro, Israel 
Midazol (FM) Hameln, Thai. 
Midolam Rafa, Israel 
Miloz Novell, Indon. 
Mizolam CCM, Malaysia 
Noctura (DI) Recalcine, Chile 
Novaplus Midazolam - 1 MG/ML - 
Injection Solution 
Hospira 
Novaplus Midazolam - 5 MG/ML - 
Injection Solution 
Hospira 
Pms-Midazolam - 1 MG/ML - Injectable Pharmascience 
Pms-Midazolam - 5 MG/ML - Injectable Pharmascience 
Relacum Pisa, Mex. 
Sedacum Dexa, Indon. 
Sedoz Claris, Philipp. 
Sopodorm ICN, Pol. 
Terap Sanitas, Chile 
Versed - 1 MG/ML - Injectable Hoffmann-La Roche 
Versed - 1 MG/ML - solution for injection Roche Pharmaceuticals 
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Versed - 2 MG/ML - Oral Syrup Roche Pharmaceuticals 
Versed - 5 MG/ML - Injectable Hoffmann-La Roche 
Versed - 5 MG/ML - solution for injection Roche Pharmaceuticals 
Versed (FM) Roche, Canad. 
Versed (FM) Roche, USA 
Versed Roche, Fr. 
Zolamid Mayne, Port. 
Zolidan (FM) BPL-Meizler, Braz. 
Zolmid Laboratorios Chile, Chile 
Zomsol Solara, Mex 
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Addendum 2. Disclosures 
 
Dr. de Wildt received an unrestricted travel grant from Roche the Netherlands to present study results 
at an international conference (1998). Dr de Wildt‟s PhD research (thesis 2001) was partially funded 
by unrestricted financial support from Roche, USA (to pay for drug analysis costs). Dr de Wildt is a 
paid consultant to Daichii Sankyo.  
 
 
